Quantification of dose perturbation by plaque in vascular brachytherapy

被引:2
|
作者
Wexberg, P
Kirisits, C
Berger, D
Sulzbacher, I
Maurer, G
Potter, R
Georg, D
Glogar, D
机构
[1] Med Univ Vienna, Dept Cardiol, Div Internal Med 2, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Radiotherapy & Radiobiol, A-1090 Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, A-1090 Vienna, Austria
关键词
atherosclerosis; dosimetry; radiochromic film; vascular brachytherapy;
D O I
10.1111/j.1365-2362.2005.01475.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Dose prescription and reporting in vascular brachytherapy (VBT) is based on the assumption that the vessel wall is water equivalent, which does not consider a possible dose perturbation by plaque. As the extent of this perturbation is unknown, we aimed to quantify dose attenuation by atherosclerotic plaque for beta- and gamma-radiation. Material and methods The dose delivered from Strontium-90/Yttrium-90 (Sr-90/Y) and Iridium-192 (Ir-192) sources with and without human peripheral arteries (Sr-90/Y: n = 38, Ir-192: n = 7) surrounding the respective delivery catheter was determined with radiochromic films. Plaque and vessel wall thickness were measured using light microscopy. From the ratio-attenuated doseunattenuated dose (dose perturbation factor: DPF) we determined averaged attenuation coefficients for atherosclerotic plaque (mu(P)) and the residual part of the vessel wall (mu(W)) by regression analysis based on the function DPF = exp(-mu(P) * plaque thickness -mu(W) * residual wall thickness). Results Attenuation in case of Ir-192 was less than the measurement uncertainties. For beta-radiation correlation was found by discrimination between calcified and noncalcified plaque. Classifying noncalcified plaque as normal arterial tissue, the regression coefficient was r = 0.845 at mu(P)= 0.5356 mm(-1) and mu(W) = 0.0663 mm(-1). Conclusions Vascular brachytherapy with beta radiation in calcified arteries results in significant dose attenuation within the vessel wall, which can be calculated on knowing the vascular morphometry. Thus, plaque thickness should be taken into account in treatment planning and retrospective analyses.
引用
收藏
页码:180 / 185
页数:6
相关论文
共 50 条
  • [41] Brachytherapy dose calculation
    Ferre, M.
    Mailleux, H.
    Pierrat, N.
    Dejean, C.
    CANCER RADIOTHERAPIE, 2013, 17 (02): : 89 - 92
  • [42] Gold nanoparticle-aided brachytherapy with vascular dose painting: Estimation of dose enhancement to the tumor endothelial cell nucleus
    Ngwa, Wilfred
    Makrigiorgos, G. Mike
    Berbeco, Ross I.
    MEDICAL PHYSICS, 2012, 39 (01) : 392 - 398
  • [43] Quantification of Atherosclerotic Coronary Plaque
    Korosoglou, Grigorios
    Katus, Hugo A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (19) : 1815 - 1816
  • [44] Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom
    Lesperance, Marielle
    Inglis-Whalen, M.
    Thomson, R. M.
    MEDICAL PHYSICS, 2014, 41 (02)
  • [45] DOSE CALCULATIONS OF FIVE RU-106 EYE PLAQUE BRACHYTHERAPY WITH MCNP4C CODE
    Jaberi, R.
    Azma, Z.
    Reza, A. Mahmood
    Hosein, Z. Mohammad
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S406 - S406
  • [46] BEDVH-A method for evaluating biologically effective dose volume histograms: Application to eye plaque brachytherapy implants
    Gagne, Nolan L.
    Leonard, Kara L.
    Huber, Kathryn E.
    Mignano, John E.
    Duker, Jay S.
    Laver, Nora V.
    Rivard, Mark J.
    MEDICAL PHYSICS, 2012, 39 (02) : 976 - 983
  • [47] The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma
    Simpson, E. Rand
    Gallie, Brenda
    Laperrierre, Normand
    Beiki-Ardakani, Akbar
    Kivela, Tero
    Raivio, Virpi
    Heikkonen, Jorma
    Desjardins, Laurence
    Dendale, Remi
    Mazal, Alexandro
    Bornfeld, Norbert
    Sauerwein, Wolfgang
    Flueehs, Dirk
    Brualla, Lorenzo
    Honavar, Santosh G.
    Reddy, Vijay Anand P.
    Suzuki, Shigenobu
    Murakami, Naoya
    Saakyan, Svetlana
    Valskiy, Vladimir
    Amiryan, Anush
    Seregard, Stefan
    All-Eriksson, Charlotta
    Hjelmqvist, Lars
    Lundell, Goran
    Sinclair, Georges
    Lundell, Marie
    Damato, Bertil
    Errington, R. Doug
    Mayles, Philip
    Mayles, Helen
    Bergstrom, Chris
    Grossniklaus, Hans
    Crocker, Ian
    Butker, Elizabeth
    Wilson, Matthew
    Haik, Barrett
    Geischen, Holger
    Patra, Pradeep
    Duker, Jay
    Mignano, John
    Rivard, Mark
    Finger, Paul T.
    Semenova, Ekaterina
    Choi, Walter
    Kalach, Nina I.
    BRACHYTHERAPY, 2014, 13 (01) : 1 - 14
  • [48] Management of Diffuse Choroidal Hemangioma with Plaque Brachytherapy
    Kocsis, J.
    Komarnicky, L. T.
    Emrich, J.
    Shields, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E632 - E632
  • [49] Ruthenium 106 Plaque Brachytherapy in Ocular Tumors
    Reddy, V. P.
    Honavar, S.
    Joshi, S.
    Ali, M.
    Ganesan, P.
    Naik, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S441 - S441
  • [50] Retina dose as risk factor for worse visual outcome in 106Ru plaque brachytherapy of uveal melanoma
    Heilemann, G.
    Fetty, L.
    Blaickner, M.
    Nesvacil, N.
    Georg, D.
    Dunavoelgyi, R.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S94 - S95